دورية أكاديمية

Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.

التفاصيل البيبلوغرافية
العنوان: Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.
المؤلفون: Ghazanfar H; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Javed N; Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Qasim A; Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Sosa F; Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Altaf F; Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Khan S; Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Mahasamudram J; Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Jyala A; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Kandhi SD; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States. skandhi@bronxcare.org., Shin D; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Mantri N; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Sun H; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Hanumanthu S; Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Patel H; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Makker J; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Balar B; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Dev A; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States., Chilimuri S; Division of Gastroenterology, Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457, United States.
المصدر: World journal of gastroenterology [World J Gastroenterol] 2024 Jul 14; Vol. 30 (26), pp. 3221-3228.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
Original Publication: Beijing : WJG Press, c1998-
مواضيع طبية MeSH: Gastroparesis*/epidemiology , Gastroparesis*/etiology , Gastroparesis*/prevention & control , Glucagon-Like Peptide-1 Receptor Agonists*/administration & dosage , Glucagon-Like Peptide-1 Receptor Agonists*/adverse effects, Aged ; Female ; Humans ; Male ; Middle Aged ; Diabetes Mellitus, Type 2/drug therapy ; Endoscopy, Gastrointestinal/adverse effects ; Endoscopy, Gastrointestinal/methods ; Gastric Emptying/drug effects ; Retrospective Studies
مستخلص: Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective in diabetes and obesity, reducing hyperglycemia by increasing insulin release and delaying gastric emptying. However, they can cause gastroparesis, raising concerns about aspiration during procedures. Recent guidelines advise discontinuing GLP-1 RA before surgery to reduce the risk of pulmonary aspiration.
Aim: To evaluate the effect of GLP-1 RAs on gastric residual contents during endoscopic procedures.
Methods: A retrospective chart review at BronxCare Health System, New York, from January 2019 to October 2023, assessed gastric residue and aspiration in GLP-1 RA patients undergoing endoscopic procedures. Two groups were compared based on dietary status before the procedure. Data included demographics, symptoms of gastroparesis, opiate use, hemoglobin A1c, GLP-1 agonist indication, endoscopic details, and aspiration occurrence. IBM SPSS was used for analysis, calculating means, standard deviations, and applying Pearson's chi-square and t-tests for associations, with P < 0.05 as being significant.
Results: During the study, 306 patients were included, with 41.2% on a clear liquid/low residue diet and 58.8% on a regular diet before endoscopy. Most patients (63.1%) were male, with a mean age of 60 ± 12 years. The majority (85.6%) were on GLP-1 RAs for diabetes, and 10.1% reported digestive symptoms before endoscopy. Among those on a clear liquid diet, 1.5% had residual food at endoscopy compared to 10% on a regular diet, which was statistically significant ( P = 0.03). Out of 31 patients with digestive symptoms, 13% had residual food, all from the regular diet group ( P = 0.130). No complications were reported during or after the procedures.
Conclusion: The study reflects a significant rise in GLP-1 RA use for diabetes and obesity. A 24-hour liquid diet seems safe for endoscopic procedures without aspiration. Patients with upper gastrointestinal symptoms might have a higher residual food risk, though not statistically significant. Further research is needed to assess risks based on diabetes duration, gastroparesis, and GLP-1 RA dosing, aiming to minimize interruptions in therapy during procedures.
Competing Interests: Conflict-of-interest statement: We have no financial relationships to disclose.
(©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
References: Am J Gastroenterol. 2024 Jun 1;119(6):1154-1157. (PMID: 37856247)
Drugs. 2021 Jun;81(8):881-893. (PMID: 33929717)
Cureus. 2018 Dec 28;10(12):e3791. (PMID: 30868005)
Adv Exp Med Biol. 2021;1307:171-192. (PMID: 32077010)
Am J Physiol. 1997 Nov;273(5):E981-8. (PMID: 9374685)
Gut. 2006 Feb;55(2):243-51. (PMID: 15985560)
Can J Anaesth. 2023 Aug;70(8):1300-1306. (PMID: 37466909)
Diabetes Metab. 2017 Oct;43(5):430-437. (PMID: 28648835)
Anesthesiology. 2024 Feb 1;140(2):346-348. (PMID: 37982170)
Front Pharmacol. 2023 Apr 06;14:1176206. (PMID: 37089939)
Nat Rev Dis Primers. 2018 Nov 1;4(1):41. (PMID: 30385743)
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211051919. (PMID: 34663102)
Can J Anaesth. 2023 Aug;70(8):1394-1396. (PMID: 36977934)
Am J Physiol Endocrinol Metab. 2008 May;294(5):E846-52. (PMID: 18334612)
Gastroenterol Clin North Am. 2015 Mar;44(1):1-7. (PMID: 25667018)
J Clin Gastroenterol. 2020 Jan;54(1):50-54. (PMID: 31135630)
J Clin Endocrinol Metab. 2006 May;91(5):1916-23. (PMID: 16492694)
J Diabetes Investig. 2023 Jun;14(6):767-773. (PMID: 36919944)
Diabetes Care. 2011 May;34 Suppl 2:S279-84. (PMID: 21525469)
Anaesthesia. 2023 Dec;78(12):1524. (PMID: 37443429)
Ann Pharmacother. 2022 Aug;56(8):922-926. (PMID: 34726082)
JAAPA. 2020 Aug;33(8):3-18. (PMID: 32740121)
Clin Exp Gastroenterol. 2013 Sep 05;6:161-5. (PMID: 24039443)
J Clin Anesth. 2023 Aug;87:111091. (PMID: 36870274)
Diabetes. 2011 May;60(5):1561-5. (PMID: 21430088)
Cureus. 2022 Jul 16;14(7):e26916. (PMID: 35983392)
Obesity (Silver Spring). 2022 Aug;30(8):1608-1620. (PMID: 35894080)
Horm Metab Res. 2019 Apr;51(4):267-273. (PMID: 30690693)
فهرسة مساهمة: Keywords: Complications; Endoscopic procedures; Gastroparesis; Glucagon-like peptide-1 agonists; Residual food
المشرفين على المادة: 0 (Glucagon-Like Peptide-1 Receptor Agonists)
تواريخ الأحداث: Date Created: 20240801 Date Completed: 20240801 Latest Revision: 20240823
رمز التحديث: 20240826
مُعرف محوري في PubMed: PMC11287410
DOI: 10.3748/wjg.v30.i26.3221
PMID: 39086638
قاعدة البيانات: MEDLINE
الوصف
تدمد:2219-2840
DOI:10.3748/wjg.v30.i26.3221